This article refers to:
Correction to: Therapies for inter-relating diabetes and obesity -- GLP-1 and obesity.
Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity -- GLP-1 and obesity. Expert Opin Pharmacother. 2014;15(17):2487-500.
Following publication of this article, errors have been identified in the placement of reference annotations. The correct annotations with their respective references are given below:
- Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004;36(11-12):747-54
- Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91(1):301-7
- Torekov SS, Kipnes MS, Harley RE, et al. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab 2011;13(7):639-43
- Torekov SS, Holst JJ, Ehlers MR. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014;16(5):451-6
- Knop FK, Aaboe K, Vilsboll T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012;14(6):500-10
- Dirksen C, Jorgensen NB, Bojsen-Moller KN, et al. Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia 2012;55(7):1890-901
- Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
- Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37(11):1443-51